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Introduction: Fractional microneedling radiofrequency (FMR) is 
an emerging treatment modality, but its effect on rosacea has 
not been studied. We sought to investigate the potential impact 
of FMR treatment on clinical improvement and histological 
changes in rosacea patients. 
Methods: A 12-week, prospective, randomized, split-face 
clinical trial was conducted. Two sessions of FMR were 
performed on one side of the face with a 4-week interval 
between treatment sessions, and the other side of the face 
remained untreated. Clinical evaluation and photometric 
measurement of erythema and histologic analysis of skin 
samples were carried out. 
Results: Clinical evaluation and photometric measurement 
revealed reduction of redness on the treated side compared 
with the untreated side and baseline. The erythema index 
decreased 13.6% and the a* value decreased 6.8% at week 12 
compared with baseline. Reduced expression of markers related 
to inflammation, innate immunity, and angiogenesis was 
observed in the immunohistochemical staining of tissue obtained 
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after FMR treatment. 
Conclusions: FMR can result in clinical and histological 
improvement of rosacea, and it can be used as an alternative or 
in combination with other treatment methods. 
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Rosacea is a chronic inflammatory skin disease, characterized 
by persistent erythema and flushing in the central face. With 
prevalence up to 22%, it severely affects the appearance of the 
sufferers, resulting in considerable psychological stress and 
low quality of life [1, 2]. 
 Although many treatment methods have been studied, there is 
no standard cure for rosacea. Currently, topical drugs, such as 
metronidazole, or oral agents, such as tetracycline antibiotics, 
are commonly used. With increasing concerns of antibiotics 
resistance, other treatment methods have been emerging. The 
effectiveness of other therapies, including pulsed dye laser and 
intense pulsed light treatments, has been also studied; however, 
these studies focused mainly on erythematotelangiectatic 
rosacea (ETR) [3, 4].  
 Fractional microneedling radiofrequency (FMR) is an emerging 
treatment modality in dermatology. FMR can deliver bipolar 
radiofrequency energy directly to the dermis with an array of 
microneedles with minimal damage of the epidermis [5]. Bipolar 
radiofrequency has been reported to induce neoelastogenesis 
and neocollagenesis and, thus, has been used in the treatment 
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of cutaneous wrinkles [6-8]. Recently, clinical and histological 
improvement of post-inflammatory erythema in acne patients 
by FMR treatment was reported [9]. Both acne and rosacea are 
categorized as sebaceous gland diseases and underlying 
inflammation is regarded as an important factor in the 
pathogenesis of these conditions. Therefore, FMR can be 
possible option for rosacea treatment by reducing inflammation. 
 The aim of this study was to investigate the impact of FMR 
treatment on the clinical improvement and histological changes 
in rosacea patients. To the best of our knowledge, this is the 





MATERIALS AND METHODS 
1. Study design and subjects  
This study was performed as a 12-week, prospective, single-
blind, randomized, and split-face clinical trial at the Department 
of Dermatology, Seoul National University Hospital, from 
January through August 2015. Subjects whose Fitzpatrick skin 
types were III or IV and who had rosacea were recruited. This 
study protocol was conducted in accordance with the 
Declaration of Helsinki and approved by the Institutional Review 
Board of Seoul National University Hospital (No. 1410-148-
622). Informed consent was acquired from all subjects prior to 
enrollment. Subjects were not allowed to use any systemic or 
topical agent for rosacea treatment during the study. 
 
2. Devices and laser treatment  
After random allocation, one side of the cheek was treated with 
FMR (INFINI®, Lutronic, Goyang, Korea; treated side) and the 
other side remained untreated (untreated side). Topical 
anesthesia with EMLA® (AstraZeneca, Södertälje, Sweden) was 
applied 30 minutes before the treatment. The FMR device can 
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deliver radiofrequency energy to the skin with applicator tip 
comprising of 49 insulated microneedles and the energy level 
(1-20) and conduction time (10-1,000 ms) are adjustable. 
The treatment in this study was done at energy level 2-3 (5-
7.5 W) for 50-70 ms, as our previous study [9]. FMR 
treatment was performed with slight overlap in two passes. 
Each patient received two sessions of treatment with a 4-week 
interval between treatments. 
 
3. Clinical outcome assessment  
Subjects visited our clinic at weeks 0 and 4 for FMR treatment 
and 4 and 8 weeks after the second session for clinical 
assessment. Digital photographs were taken at every visit using 
the same camera settings (EOS 600D®; Canon, Tokyo, Japan). 
Two independent dermatologists conducted clinical 
assessments with the photographs. Improvement of rosacea 
was assessed using Investigator’s Global Assessment scale 
(IGA; Table 1) and the Kappa value was 0.77 (p < 0.001), 
showing good agreement between assessors. The objective 
measurement of erythema was performed with two photometric  
devices (DermaSpectrometer®; Cortex Technology, Hadsund,  
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Table 1. Investigator’s global assessment  
Grade Degree of improvement 
0 No improvement 
1 0-10% 






Denmark; Spectrophotometer CM-2002®; Konica Minolta, 
Tokyo, Japan). Patients’ subjective assessments of pain were 
surveyed just after each treatment session. Subjective 
therapeutic effectiveness and satisfaction score were surveyed 
at weeks 4, 8, and 12. Some patients also subjectively assessed 
the change in their rosacea symptoms (persistent erythema, 
flushing, papule or pustule, telangiectasis, burning or pricking 
sensation, itching sensation, edema, and heat sensation) by 
percentage at Week 12. 
 
4. Histopathology and immunohistochemistry  
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Skin biopsies were performed from one side at week 0 and 
from both sides of the face at week 8 in 5 patients. Tissue 
sections were stained with hematoxylin-eosin (H&E) and 
toluidine blue. The number of mast cells with granules stained 
purple with toluidine blue was counted. For assessing molecular 
changes before and after FMR treatment, tissue samples were 
processed for immunohistochemical (IHC) staining for 
interleukin(IL)-8, NF-κB, toll-like receptor (TLR)-2, LL-
37, vascular endothelial growth factor (VEGF), and transient 
receptor potential transient receptor potential vanilloid (TRPV) 
2, 3, and 4 (Abcam, Cambridge, England). The intensity of the 
IHC stain was measured with a semi-quantitative method using 
an image analysis program (Leica QWin version 3.5.1, Leica 
Microsystems, Wetzlar, Germany) by detecting the area of 
NovaRED™ (Vector Laboratories, CA, USA) staining with a 
color threshold.  
 
5. Statistical analyses  
We performed statistical analyses using the Statistical Package 
for the Social Sciences version 20 (SPSS Inc., Chicago, IL, 
USA). We used the Student’s t test or paired t-test to 
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compare continuous variables obtained with photometric 
devices and the Mann-Whitney U test for comparing IGA and 






Twenty-one patients (1 man, 20 women) completed the study. 
The mean age of the subjects was 42.9 ± 10.3 years. Thirteen 
patients had Fitzpatrick skin type III, and 8 patients had 
Fitzpatrick skin type IV. Fourteen patients had ETR, and 7 had 
papulopustular rosacea (PPR). The mean values of the 
erythema index were 17.8 and 17.0 for the treated and 
untreated sides, respectively, and those of the a* values were 
10.6 and 10.4 for the treated and untreated sides at baseline, 
respectively, showing no significant differences between the 
two sides (p = 0.441 and 0.672). There was no serious 
adverse effect resulting in a patient discontinuing from the 
study.  
 
Clinical improvement and safety 
Clinical improvement of rosacea was observed in 17 (81.0 %) 
of 21 total patients on the FMR-treated side. The mean IGA 
scores were 1.05, 1.57, and 2.00 for the treated side and 0.29, 
0.38, and 0.38 for the untreated side at weeks 4, 8, and 12, 
respectively (p = 0.016, p = 0.007, p < 0.001) (Figure 1). 
Among the 17 patients with improvement, the mean IGA score 
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was 2.47 at week 12, which indicates approximately 20 % 
improvement. Figure 2 represents improvement of erythema on 
the treated side and minimal change on the untreated side.  
 Photometric measurements revealed significant reduction of 
redness on the treated side compared with the untreated side 
and baseline (Figure 3). The erythema index decreased 11.9 %, 
10.7 %, and 13.6 % (p = 0.003, p = 0.006, p < 0.001) and the 
a* value decreased 6 %, 5.8 %, and 6.8 % (p < 0.001, p = 0.001, 
p < 0.001) at weeks 4, 8, and 12, respectively, compared with 
baseline. The a* value decreased 10.5 % in the PPR patients 
and 4.9 % in the ETR patients, which was a statistically 




Figure 1. Changes in investigator’s global assessment 
Treated side showed improvement of rosacea with increasing 







Figure 2. Clinical photographs showing improvement of rosacea. 
The treated side showed decreased erythema and papules, 









Figure 3. Photometric measurements of erythema in the treated 
side and untreated side. 
Mean erythema index (A) and a* scale (B) decreased in the 
treated side, compared with baseline (week 0) and the 
untreated side. *: p < 0.05 compared with week 0; †: p < 0.05 
compared with the untreated side. 
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Patient’s subjective assessment  
The mean values of subjective therapeutic effectiveness were 
3.7 ± 1.1 at week 4, 5.3 ± 1.3 at week 8, and 5.9 ± 1.7 at week 
12. Satisfaction scores were 5.1 ± 1.4 at week 4, 5.7 ± 1.0 at 
week 8, and 6.2 ± 1.6 at week 12. The mean pain scores were 
3.1 ± 1.6 and 3.1 ± 1.4 after the first and second treatment 
sessions, respectively. 
 Seventeen patients (81.0%) provided assessments of their 
rosacea symptoms at week 12. Patient-reported improvement 
of symptoms were as follows: papule or pustule, 57.5 % (n = 
4); itching sensation, 48.3 % (n = 3); heat sensation, 28.3 % (n 
= 15); persistent erythema, 28.2 % (n = 17); burning or 
pricking sensation, 27.9 % (n = 7); transient erythema, 25.6 % 
(n = 17); telangiectasis, 18.6 (n = 7); and edema, 5 % (n = 1).  
 
Histologic findings  
H&E staining of skin samples revealed reduced dermal 
inflammation after 2 sessions of FMR treatment (Figure 4A). 
The average mast cell count decreased from 10.8 at week 0 to 
5.0 on the treated side at week 8 (p = 0.024). The cell count 
on the treated side was also significantly lower than that on the 
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untreated side (5.0 vs. 12.2; p = 0.036). In image analysis, an 
overall decrease of IHC intensity in the tissue obtained from the 
treated skin at week 8 was observed (Figure 4B). All the 
markers related to angiogenesis (VEGF), inflammation (NF-κB 
and IL-8), innate immunity (LL-37 and TLR2), and 
neuroimmunity (TRPV 2, 3, and 4) showed significantly 
decreased intensities for the treated side compared with 
baseline (week 0). Compared with the untreated side, all the 
markers except TLR2 and TRPV3 were reduced in the tissue 










Figure 4. Histologic analysis of skin specimen. 
H&E and toluidine blue staining showed decreased overall 
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dermal inflammation and mast cell counts (A) (H&E original 
magnification X100 and toluidine blue original magnification 
X400). Image analysis of immunohistochemistry staining 
showed overall decrease of markers related to angiogenesis, 
inflammation, innate immunity, and neuronal cation channels 
(B). *: p < 0.05 compared with week 0; †: p < 0.05 compared 







Although radiofrequency devices are not lasers, they have been 
gaining attention in dermatology. Ruiz-Esparza et al. reported a 
possible role of radiofrequency for the treatment of rosacea 
[10]; however, the treatment of rosacea with radiofrequency 
devices and its mechanism have rarely been reported. Our 
results confirmed that FMR can result in modest improvement 
of rosacea. The effectiveness was maintained until 2 months 
after the last treatment. FMR was slightly more effective in 
reducing erythema in patients with PPR than in those with ETR, 
suggesting inflammatory lesions, such as papules and pustules, 
could be more effectively treated with this device. This result 
agreed with reports showing that FMR is effective in treating 
inflammatory acne [11].  
 Subjective symptom improvements showed more dramatic 
differences than other assessments. All the patients who 
answered questions regarding symptom changes assessed that 
not only persistent erythema but also transient erythema 
(flushing) decreased. This means that FMR can alleviate the 
aggravation of erythema between treatment sessions without 
other treatments. While there was an overall increase of 
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measured erythema at week 8 compared with week 4 on the 
untreated side, the increase in measured erythema on the 
treated side was minimal. Reduction of other subjective 
symptoms including sensations of itching, heat, and burning or 
pricking also showed the effectiveness of FMR on rosacea 
symptom control. 
 The mechanism of FMR had been suggested as remodeling of 
dermal structure and decreasing sebaceous gland activity by 
skin needling and the thermal effect of radiofrequency energy 
[12, 13]. However, we previously found that FMR may have 
anti-inflammatory and anti-angiogenesis effects, because NF-
κB, IL-8, and VEGF decreased in vivo after FMR treatment 
[9]. The expression of VEGF is up-regulated in the lesional 
skin of rosacea patients, and NF-κB can up-regulate IL-8 
and VEGF expression through binding to the NF-κB sites of 
the promoter of these genes [14, 15]. Although a detailed 
mechanism of regulating NF-κB by FMR is unclear, the results 
of this study show that FMR can reduce inflammation and 
angiogenesis in rosacea. 
 Furthermore, the decrease of markers related to the innate 
immune system (TLR2 and LL-37) was also observed after 
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FMR treatment. Dysregulation of the innate immune system is 
thought to be important in the pathogenesis of rosacea. In 
rosacea patients, increased levels of TLR2 lead to higher 
expression of kallikrein 5, resulting in increased expression of 
LL-37 [16, 17]. LL-37 can induce leukocyte chemotaxis and 
angiogenesis [16, 18]. The candidates of triggers for TLR2 
activation include Demodex mites and the Demodex-associated 
bacterium Bacillus oleronius [19, 20]. The heat produced by 
FMR treatment possibly killed the mites or bacteria, resulting in 
suppression of the overactivated innate immune system. 
 Mast cells are also thought to contribute to inflammation and 
angiogenesis in rosacea patients and are regarded as key 
mediators of cathelicidin LL-37-initiated skin inflammation [21, 
22]. Although the exact mechanism remains elusive, we found 
that mast cell count decreased after FMR treatment, which 
could be a possible pathway to reduce inflammation and 
angiogenesis. The possible mechanisms of FMR against rosacea 
are shown in Figure 5. 
 Sulk et al. observed increased dermal immunostaining of TRPV 
2, 3, and 4 in rosacea [23]. TRPVs are thought to be involved 
in inflammation, innate immunity, nociception, heat sensation, 
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 Figure 5. Possible mechanisms of fractional microneedling 
radiofrequency (FMR) treatment in rosacea 
FMR may regulate inflammation and angiogenesis in the rosacea 
skin via various pathways. 
 
and vascular regulation, and they can mediate and maintain the 
symptoms of rosacea [24]. In our study, reduced expression of 
TRPVs after FMR treatment correlated with improvements of 
subjective symptoms including flushing and sensations of 
burning or pricking and heat. However, because these markers 
can be expressed in immune cells, decreased expression of 
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TRPVs could be the result of fewer inflammatory cells in the 
tissue from the treated side.  
 The limitation of this study is that the number of patients 
enrolled was rather small. Also, there were fluctuations of 
erythema at the time of visit due to flushing the nature of 
rosacea. Because this study was performed during the winter 
through summer, there could be seasonal variations in UV and 
temperature, which influence aggravation or improvement of 
rosacea symptoms. 
 In conclusion, FMR results in clinical and histological 
improvement of rosacea. FMR can be an option for patients who 
fail other medical therapy, who are resistant to long-term oral 
therapy, or who do not want take any oral or topical medication, 
such as pregnant women. We also expect that FMR may have 
synergistic effects in combination with other treatment methods. 
Further study is to be focused on optimizing parameters as well 
as evaluating the efficacy of multiple FMR treatments and 
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서론: Fractional microneedling radiofrequency (FMR)는 새로 
떠오르고 있는 치료법이지만, 주사에 대한 효과에 대해서는 기존에 
연구된 바 없다. 이에 본 연구에서는 주사 환자에서 FMR 치료의 
임상적 및 조직학적 효과에 대해 알아보고자 한다.  
방법: 12 주 동안의 전향적, 무작위배정, split-face 방식의 임상 
연구를 시행하였다. 안면 한 쪽에 4 주 간격으로 2 회의 FMR 
치료를 시행하였고, 다른 쪽 안면은 치료하지 않고 두었다. 임상 
평가와 홍반에 대한 광학적 측정, 조직학적 분석을 시행하였다.  
결과: 임상 평가와 광학적 측정 결과 치료한 쪽 안면에서 치료하지 
않은 쪽 안면 및 치료 전 안면과 비교하여 모두 홍반의 감소가 
나타났다. 치료 전과 비교하여 12 주 째 치료한 쪽 안면에서 
erythema index 는 13.6%, a* 값은 6.8% 감소하였다. 
면역조직화학 염색에서 FMR 치료 후 염증, 선천면역, 혈관생성 
관련 인자들의 발현이 감소됨이 관찰되었다.  
결론: FMR 치료는 임상적 및 조직학적으로 주사를 호전시킬 수 
있으며, FMR 은 다른 치료법에 대한 대체방법으로, 또는 다른 
치료법과 함께 사용될 수 있겠다. 
------------------------------------- 
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